1 / 10

Optimizing Vincristine Dosing for Children

Optimizing Vincristine Dosing for Children. Indiana CTSI Retreat 2011. Vincristine is the most commonly used pediatric anticancer agent. Uses Childhood ALL Lymphoma Wilms Pediatric sarcomas Pediatric brain tumors. Toxicities Neuropathy Severe vesicant SIADH Alopecia

nariko
Download Presentation

Optimizing Vincristine Dosing for Children

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Optimizing Vincristine Dosing for Children Indiana CTSI Retreat 2011

  2. Vincristine is the most commonly used pediatric anticancer agent • Uses • Childhood ALL • Lymphoma • Wilms • Pediatric sarcomas • Pediatric brain tumors • Toxicities • Neuropathy • Severe vesicant • SIADH • Alopecia • Minimal hematologic toxicity

  3. Clinical Biomarkers of CIPN • Age • Race • Treatment schedule • Cumulative chemotherapy dose • Concomitant medications • Baseline peripheral neuropathy

  4. Caucasians and low CYP3A5 expressers experience more VIPN • 34.8% of Caucasians vs. 4.5% of African-Americans with ALL (p=0.004) • Cumulative VIPN score greater in low CYP3A5 expressers: 13.9 ± 11.2 vs. 7.2 ± 5.5 (p=0.0003) Renbarger JL et al. Pediatr Blood Cancer 2008 Apr;50(4):769-71. Egbelakin A, Ferguson M et al. Pediatr Blood Cancer 2011 Mar;56(3):361-7. PMID: 21225912

  5. Dose-corrected M1 concentration associated with age and CYP3A5 Black = CYP3A5 *0*0 Red = CYP3A5 *1*0 Green = CYP3A5*1*1 p= 0.0033 Lehmann AS et al. 2010 ASCO # 9523

  6. NOT-RR-09-005 • Administrative Supplements for Research on Outcome Measures for Pediatric Clinical Trials in support of the BPCA • Purpose…to stimulate collaborative, multidisciplinary basic and clinical research to: • Facilitate development of qualified outcome measures • Relate non-clinical to clinical outcome assessments in child health for improving the evaluation of interventions • Assess and interpret clinical outcomes

  7. The Next Step Toward Optimization of Vincristine Dosing • ADVANCE Multicenter trial: IU, UM, CNMC, VU • Enroll kids at time of diagnosis and prospectively follow them • Neuropathy phenotype: TNS and NPS (CTSI supplement award) • Vincristine pathway PG, PK, modeling (RC1) • Vincristine PG in Kenyan children

  8. Goal: optimize vincristine dosing • Build a prediction model of vincristine neuropathy: • Clinical data • Disease data • Vincristine metabolomics/PK • Vinca pathway genomics

  9. PROPEL • Indiana University • Children’s National Medical Center • University of Michigan • Vanderbilt University

  10. Acknowledgements IU Simon Cancer Center Clinical Pharmacology Analytic Core Laboratory David Jones Andi Masters University of Michigan Raymond Hutchinson Ellen Smith Children’s National Medical Center Roger Packer Vanderbilt University Richard Ho NIH 1RC1CA146882 UL1 RR 025761-02S5 NIH K23 RR019956 IUPUI Biomedical Research Grant Showalter Research Trust Fund Clarian Values Fund for Research Indiana University Division of Clinical Pharmacology Jennifer Dennison Sara Quinney Lang Li David Flockhart Stephen Hall Section of Pediatric Hematology/Oncology, Indiana University Amalia Lehmann AkinbodeEgbelakin Michael Ferguson Ariel Topletz Joy Rupenthal/Nicole Robinson Cindy Elkins Anne Bubnick

More Related